[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-415682-105":59,"doc-detail-415682-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","off-label-applications-of-omalizumab-current-insights-and-perspectives","Off-label applications of omalizumab: Current insights and perspectives","","Omalizumab is a humanized monoclonal antibody that binds free IgE, interrupting allergic cascades and IgE-mediated inflammation. After decades of market use and supporting studies, it shows strong tolerability and a favorable safety profile. Approved in Europe for allergic asthma, chronic spontaneous urticaria, and chronic sinusitis with polyps, and in the United States for allergic asthma, chronic spontaneous urticaria, and pediatric food allergies, it may broaden biologic options. Reviews compile current evidence for uses beyond registered indications.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/off-label-applications-of-omalizumab-current-insights-and-perspectives/415682/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/off-label-applications-of-omalizumab-current-insights-and-perspectives/415682.png","ImageObject",300,407,{"name":92,"@type":93},"นรินทร์","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is omalizumab and how does it work against allergy?","Question",{"text":113,"@type":114},"Omalizumab binds free IgE and prevents IgE from interacting with receptors on effector cells, reducing receptor expression and inhibiting allergic cascades and IgE-mediated inflammation.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which indications for omalizumab are described in Europe and the United States?",{"text":118,"@type":114},"In Europe, it is registered for allergic asthma, chronic spontaneous urticaria, and chronic sinusitis with polyps. In the United States, it covers allergic asthma, chronic spontaneous urticaria, and chronic food allergies in children over 1 year of age.",{"name":120,"@type":111,"acceptedAnswer":121},"What new off-label uses does the document focus on?",{"text":122,"@type":114},"It summarizes knowledge on omalizumab use in conditions beyond current product registration, including reports as adjuvant or monotherapy for allergic conjunctivitis, systemic mastocytosis, food allergies, drug hypersensitivity, allergic bronchopulmonary aspergillosis, and allergen immunotherapy.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},415682,1790793916,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":4},2336475104957,"https://ap-avatar.wpscdn.com/avatar/22000c4c6bd8a5076e1?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787554080175789136","Jaromin, Wardzyska World Allergy Organization Journal (2025) 18:101156 [http://doi.org/10.1016/j.waojou.2025.101](http://doi.org/10.1016/j.waojou.2025.101)156  \nREVIEW  \nOpen Access  \nOff-label applications of omalizumab: Current insights and perspectives  \nAleksandra Jaromin, MD and Aleksandra Wardzy ska, MD, PhD*  \nABSTRACT  \nOmalizumab is a humanized monoclonal antibody that binds free IgE. Consequently, it exhibits inhibitory properties against allergic cascades. Over the past 20 years, omalizumab has been in the market, and studies have shown its strong tolerability and safety profile. Since 2003 in the United States of America and 2005 in Europe, omalizumab has been available to patients as a therapeutic option. In Europe, it is registered for the treatment of allergic asthma, chronic spontaneous urticaria, and chronic sinusitis with polyps. In the United States, it has been registered for the treatment of allergic asthma, chronic spontaneous urticaria, and chronic food allergies in children over 1 year of age. With a universal target point for most allergic conditions, omalizumab has the potential to become the most versatile biological drug for allergologists. The literature describes numerous uses of omalizumab as an adjuvant or monotherapy for allergic conjunctivitis, systemic mastocytosis, food allergies, drug hypersensitivity, allergic bronchopulmonary aspergillosis, and allergen immunotherapy, among others. In the following publication, we will provide you with the current knowledge regarding the use of omalizumab in conditions other than those covered by the current product registration.  \nKeywords: Omalizumab, Food allergy, Off-label, SCIT, Drug hypersensitivity  \nINTRODUCTION  \nIn 2005, omalizumab (OMA) was approved for marketing in the European pharmaceutical market. It is an antibody against IgE that binds immunoglobulins of this class and prevents them from binding to specific receptors, which then reduces the expression of receptors on the effector cells. This results in inhibition of the allergic cascade and IgE-mediated inflammation. Initially, OMA was used in the treatment of moderate or severe asthma, and over time, it was added to the indication for the treatment of chronic spontaneous urticaria (since 2014) and  \nchronic rhinosinusitis with polyps (since 2020) . Since February 2024 in the United States of America, omalizumab can also be used to treat food allergies in adults and children as young as 1 year of age. Over more than 2 decades on the market, the safety of OMA has been proven, in real-life studies, and when used, the most common side effects include mild and usually selflimiting local reactions. The risk of anaphylaxis and other serious side effects was relatively low.1 The incidence of cardiovascular events, cancer, infection, and impact on pregnancy has not been determined, especially in the long term (currently, the longest observations last about 20  \nDepartment of Immunology and Allergy, Medical University of Lodz, Poland *Corresponding author. Department of Immunology and Allergy, Medical University of Lodz, 251 Pomorska Str, 92-213 Lodz, Poland. E-mail:  \n[aleksandra.wardzynska@umed.lodz.pl](aleksandra.wardzynska@umed.lodz.pl)  \nFull list of author information is available at the end of the article.  \n[http://doi.org/10.1016/j.waojou.2025.101156](http://doi.org/10.1016/j.waojou.2025.101156)  \nReceived 10 September 2025; Received in revised from 14 October 2025; Accepted 26 November 2025  \nOnline publication date xxx  \n1939-4551/© 2025 The Authors. Published by Elsevier Inc. on behalf of World Allergy Organization. This is an open access article under the CC BY license ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)).  \n2 Jaromin, Wardzyska World Allergy Organization Journal (2025) 18:101156 [http://doi.org/10.1016/j.waojou.2025.101](http://doi.org/10.1016/j.waojou.2025.101)156  \nyears) . Observing the dynamic development of immunology and a","cbCaiu4Q9p7SN43p","https://ap.wps.com/l/cbCaiu4Q9p7SN43p","pdf",1378155,15,"English","# Abstract\n# Introduction\n# Mechanisms of Action of Omalizumab","[{\"question\":\"What is omalizumab and how does it work against allergy?\",\"answer\":\"Omalizumab binds free IgE and prevents IgE from interacting with receptors on effector cells, reducing receptor expression and inhibiting allergic cascades and IgE-mediated inflammation.\"},{\"question\":\"Which indications for omalizumab are described in Europe and the United States?\",\"answer\":\"In Europe, it is registered for allergic asthma, chronic spontaneous urticaria, and chronic sinusitis with polyps. In the United States, it covers allergic asthma, chronic spontaneous urticaria, and chronic food allergies in children over 1 year of age.\"},{\"question\":\"What new off-label uses does the document focus on?\",\"answer\":\"It summarizes knowledge on omalizumab use in conditions beyond current product registration, including reports as adjuvant or monotherapy for allergic conjunctivitis, systemic mastocytosis, food allergies, drug hypersensitivity, allergic bronchopulmonary aspergillosis, and allergen immunotherapy.\"}]","Off-label applications of omalizumab: Current insights and perspectives | PDF",1790602411,38]